For example, studies have shown the efficacy of biologicals targeting interleukin-5 (IL-5) and interleukin-4/13 (IL-4/13) in asthma [106] and the effectiveness of nintedanib, a tyrosine kinase inhibitor, in slowing the progression of IPF [107]. Here, IL4 is linked to idiopathic pulmonary fibrosis.